Drug Profile
Quinotolast
Alternative Names: FK 021; FR 71021Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Fujisawa
- Developer Astellas Pharma; Fujisawa
- Class Antiallergics; Antiasthmatics; Antiulcers; Cytoprotectives; Quinolizines; Small molecules; Tetrazoles
- Mechanism of Action Cell membrane modulators; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Irritable bowel syndrome
- Discontinued Asthma; Peptic ulcer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in Japan (PO)
- 30 Nov 2009 Preclinical trials in Irritable bowel syndrome in Japan (PO)
- 25 Nov 2009 Pharmacodynamics data from preclinical studies in Irritable bowel syndrome presented at the GASTRO-2009 Joint Meeting (GASTRO-2009)